CDR 208
Alternative Names: CDR-208Latest Information Update: 30 Dec 2024
Price :
$50 *
At a glance
- Originator CDR-Life
- Class Antibodies; Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 09 Sep 2024 Discontinued for Solid tumours in Switzerland (Parenteral), before September 2024 (CDR Life pipeline, September 2024)
- 06 Aug 2024 Early research in Solid tumours in Switzerland (Parenteral) (CDR Life pipeline, August 2024)